Feng Zhang (Susan Walsh/AP Images)

Broad In­sti­tute lands ma­jor vic­to­ry in CRISPR patent fight over UC Berke­ley, No­bel win­ners

Em­manuelle Char­p­en­tier and Jen­nifer Doud­na have their No­bel prizes in chem­istry for their CRISPR-Cas9 DNA scis­sors, but the US Patent and Trade­mark Of­fice made clear late Mon­day that Har­vard-MIT’s Broad In­sti­tute and su­per­star re­searcher Feng Zhang con­trol the patents in­volv­ing claims to CRISPR-Cas9 sys­tems for use in eu­kary­ot­ic (have a nu­cle­us) cells.

The de­ci­sion was an­oth­er huge le­gal blow to the No­bel prize win­ners, as well as the Uni­ver­si­ty of Cal­i­for­nia and Uni­ver­si­ty of Vi­en­na, and com­pa­nies like In­tel­lia Ther­a­peu­tics and Char­p­en­tier-found­ed CRISPR Ther­a­peu­tics, which do not have li­cens­es with the Broad In­sti­tute. In­tel­lia, which al­so re­leased some ear­ly CRISPR da­ta on Mon­day, saw its stock price fall by about 9% af­ter hours on Mon­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.